Evolv Q1 2026 Prepared Remarks Confirm Decelerating Growth and Persistent Challenges

What happened

Evolv Technologies Q1 2026 prepared remarks, released on May 18, 2026, reiterated management’s prior guidance for FY2026 revenue of $160-165M (11-13% YoY growth) and ARR growth of at least 20%, confirming a slowdown from the 37-40% top-line growth in FY2025. The prepared remarks highlighted the ongoing transition to a full subscription model as high-margin distributor license fees continue to run off to zero, pressuring near-term gross margins. Subscription gross margin remained in the mid-50% range, dragged down by equipment disposal and field service costs on first-generation Express units, while product margins stayed negative. Legal overhangs—including securities class actions and an FTC order—were not resolved, and management noted continued work on remediating material internal control weaknesses. The overall tone was measured, with no upward revision to cash flow or profitability outlook, reinforcing that the business is still capital-intensive and dependent on scale to deliver self-funding.

Implication

The Q1 2026 prepared remarks validate the DeepValue report's base case scenario of decelerating revenue growth (~11-13%) and ARR growth of ~20%, with adjusted EBITDA margins in the mid-single-digit range. The lack of positive surprises on cash flow or legal resolution suggests that the stock's recent rally to $7.13 (up ~80% in the past year) is not supported by a change in fundamentals. With a market cap of $1.17B and negative GAAP earnings, any disappointment on growth or an adverse legal outcome would compress the multiple further. Existing holders should consider trimming above $7, as the risk of reversion to the $5.50 attractive entry level or below remains significant. New buyers should wait for either a better entry price (below $5.50) or clearer evidence of improving subscription margins and self-funded expansion before initiating a position.

Thesis delta

The Q1 2026 prepared remarks did not introduce any material new information that alters the existing investment thesis. The company is executing as guided, but the deceleration in growth and persistent margin and legal headwinds keep the risk-reward unfavorable at the current valuation. No change in the negative view; the thesis remains that the stock lacks margin of safety given a market cap of ~$1.17B against negative GAAP earnings and unresolved uncertainties.